NH SEC Filings - NantHealth Inc- Annual Report, Proxy Statement, Prospectus

Basic Stats

LEI	549300Z86EF5CSQMW346
CIK	1566469

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NantHealth Inc

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

February 13, 2024	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37792 NantHealth, Inc. (Exact name of registrant as specified in its cha
February 8, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2024 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File N
January 25, 2024	S-8 POS	As filed with the Securities and Exchange Commission on January 25, 2024 As filed with the Securities and Exchange Commission on January 25, 2024 Registration No.
January 25, 2024	S-8 POS	As filed with the Securities and Exchange Commission on January 25, 2024 As filed with the Securities and Exchange Commission on January 25, 2024 Registration No.
January 25, 2024	POS AM	As filed with the Securities and Exchange Commission on January 25, 2024. As filed with the Securities and Exchange Commission on January 25, 2024. Registration No. 333-256474 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 NANTHEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 27-3019889 (State or other jurisdiction of inc
January 25, 2024	POS AM	As filed with the Securities and Exchange Commission on January 25, 2024. As filed with the Securities and Exchange Commission on January 25, 2024. Registration No. 333-254937 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 NANTHEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 27-3019889 (State or other jurisdiction of inc
January 25, 2024	S-8 POS	As filed with the Securities and Exchange Commission on January 25, 2024 As filed with the Securities and Exchange Commission on January 25, 2024 Registration No.
January 2, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 26, 2023 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
December 21, 2023	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2023 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
November 22, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantH
November 14, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-37792 CUSIP Number: 630104305 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Read Instructions (on back page) Before Preparing Form.
November 1, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 26, 2023 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File N
October 5, 2023	8-K	Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 29, 2023 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
September 26, 2023	SC 13D	US6301043054 / NantHealth Inc / Summus Holdings LLC - SC 13D Activist Investment SC 13D CUSIP No. 630104305 SCHEDULE 13D Page 1 of 8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 NantHealth, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 630104305 (CUSIP Number) Summus Holdings, LLC Attn: Rao Haris Naseem 2871 Lake Vista Drive, Suite 210 Lewisville,
September 26, 2023	EX-99.1	Joint Filing Agreement, dated as of September 22, 2023, by and between Summus Holdings, LLC, and Rao Haris Naseem. EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-l (k)(l) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concernin
September 13, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 7, 2023 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
September 13, 2023	EX-10.1	Employment Agreement between Rao Haris Naseem and NantHealth, Inc. Exhibit 10.1 NANTHEALTH, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into as of the Effective Date (as defined below) by and between NantHealth, Inc. (the “Company”), and Rao Haris Naseem (“Executive”). 1.Duties and Scope of Employment. (a)Positions and Duties. As of September 7, 2023 (the “Start Date”), Executive will serve as the Company’s
September 7, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Schedule 13D (including any and all amendments thereto) with respect to the common stock, par value $0.0001 per share, of NantHealth, Inc., and further agree that this Joint Filing
September 7, 2023	SC 13D	US6301043054 / NantHealth Inc / Nant Capital, LLC - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 NantHealth, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 630104305 (CUSIP Number) Nant Capital, LLC Attn: Charles Kenworthy 450 Duley Road El Segundo, California 90245 (310) 836-6400 With a copy to: Martin J. Waters
August 30, 2023	EX-10.1	Stock Purchase Agreement, dated August 28, 2023, by and among the Issuer and the Purchasers (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K (File No. 001-37792) filed with the SEC on August 30, 2023). Exhibit 10.1 STOCK PURCHASE AGREEMENT BY AND BETWEEN NANTHEALTH, INC., AND EACH OF THE PURCHASERS AS SET FORTH HEREIN AUGUST 28, 2023 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of Common Stock 4 2.1 Purchase and Sale 4 2.1 Closing; Delivery. 4 3. Additional Capital Commitment 6 4. Representations and Warranties of the Company 6 4.1 Organization and Power 6 4.2 Capitalization 6 4.3 Aut
August 30, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 28, 2023 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Nu
August 22, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantHealth
August 22, 2023	EX-10.1	Company, National Association, a national banking association, as successor in interest to U.S. Bank National Association, as trustee, and U.S. Bank Trust Company EXHIBIT 10.1 FIRST SUPPLEMENTAL INDENTURE This First Supplemental Indenture (this “Supplemental Indenture”), dated as of May 17, 2023, among NantHealth, Inc., a Delaware corporation (the “Company”), NaviNet, Inc., a Delaware corporation (the “Original Subsidiary Guarantor”), OpenNMS Group, Inc., a North Carolina corporation (the “Additional Subsidiary Guarantor”, and, together with the Original Su
August 15, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-37792 CUSIP Number: 630104305 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Read Instructions (on back page) Before Preparing Form.
August 10, 2023	CORRESP	* * * * July 28, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance – Office of Technology 100 F Street, N.E. Washington, D.C. 20549 Attention: Joseph Cascarano Robert S. Littlepage Re: NantHealth, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed April 14, 2023 File No. 001-37792 Dear Joseph Cascarano and Robert Littlepage: We submit this letter in respo
May 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2023 NantHealth, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2023 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Numbe
May 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2023 NantHealth, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2023 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Numbe
May 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2023 NantHealth, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2023 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Numbe
May 15, 2023	EX-10.2	Subordination Agreement, dated March 2, 2023, by and between the Registrant, NaviNet, Inc., Airstrip Technologies, Inc. and Nant Capital, LLC Exhibit 10.2 Subordination Agreement March 2, 2023 Morrisville, North Carolina This Subordination Agreement (this “Agreement”), dated March 2, 2023, is made between NantHealth, Inc., a Delaware corporation, with offices at 3000 RDU Center Drive, Suite 200, Morrisville, North Carolina 27500 (the “Company”), NaviNet, Inc., a Delaware corporation (the “Subsidiary Guarantor”), Nant Capital, LLC, a Del
May 15, 2023	EX-10.4	Amendment No. 1 to Shared Services Agreement, dated as of March 24, 2023, by and between the Registrant and NantWorks, LLC Exhibit 10.4 AMENDMENT NO. 1 TO SHARED SERVICES AGREEMENT This Amendment No. 1 (the “Amendment”) is made as of the date of the last signature below and shall be effective as of March 16, 2023 (the “Amendment Effective Date”), by and between NantHealth, Inc. (formerly Nant Health, LLC), a Delaware corporation (“NantHealth” or the “Company”), and NantWorks, LLC, a Delaware limited liability company
May 15, 2023	EX-10.3	Letter Agreement, dated March 2, 2023, by and between the Registrant and the beneficial owners Exhibit 10.3 LETTER AGREEMENT This LETTER AGREEMENT (this “Agreement”) is made and entered into as of March 2, 2023 between NantHealth, Inc., a Delaware corporation (the “Company”), and the beneficial owners listed on Exhibit A (the “Holders”). RECITALS WHEREAS, the Holders are collectively the beneficial owners of $137,500,000 aggregate principal amount of the Company’s 4.50% Convertible Senior N
May 15, 2023	EX-10.1	Credit Agreement, dated as of March 2, 2023, by and between the Registrant, certain subsidiaries of the Registrant, as the guarantors, the lender parties Certain identified information marked with [***] has been excluded from this exhibit because it is not material and is of the type that the registrant treats as private and confidential.
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantHealt
May 8, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2023 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Number
May 1, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37
April 14, 2023	EX-21.1	NantHealth, Inc. Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom NantHealth Labs, Inc. Delaware The Open NMS Group, Inc. North Carolina OpenNMS Group Canada, Inc. Canada Exhibit 21.1 NantHealth, Inc. Subsidiaries Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom NantHealth Labs, Inc. Delaware The Open NMS Group, Inc. North Carolina OpenNMS Group Canada, Inc. Canada Note: Subsidiary companies excluded from the above listing, if considered in the aggregate, would not constitute a significant subsidiary.
April 14, 2023	EX-10.3	Equity Incentive Plan, as Amended and Restated, and related form agreement Exhibit 10.3 NANTHEALTH, INC. 2016 EQUITY INCENTIVE PLAN (As Amended and Restated December 15, 2022) 1.Purposes of the Plan. The purposes of this Plan are: •to attract and retain the best available personnel for positions of substantial responsibility, •to provide additional incentive to Employees, Directors and Consultants, and •to promote the success of the Company’s business. The Plan permits t
April 14, 2023	EX-4.1	Description of Securities Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 NantHealth, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our Common Stock. Description of Common Stock The following description of our Common Stock is a summary and does not purport
April 14, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37792 NantHealth, In
March 31, 2023	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-37792 CUSIP Number: 630104305 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Read Instructions (on back page) Before Preparing Form.
March 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 2, 2023 NantHealth, Inc. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 2, 2023 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Numb
March 6, 2023	EX-99.1	NantHealth Announces $22.5 Million New Financing with Highbridge and Nant Capital Exhibit 99.1 NantHealth Announces $22.5 Million New Financing with Highbridge and Nant Capital Morrisville, NC – March 6, 2023 — NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced the entry into a credit agreement for a new senior secured term loan in an aggregate principal amount of $22
December 15, 2022	EX-99.1	NantHealth, Inc. Announces 1-For 15 Reverse Stock Split Exhibit 99.1 Investor Contact: Robert Jaffe 424.288.4098 [email protected] NantHealth, Inc. Announces 1-For 15 Reverse Stock Split Morrisville, NC ? December 15, 2022 ? NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that the company has implemented a reverse stock split at a ratio
December 15, 2022	EX-3.1	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of NantHealth, Inc., dated as of December 15, 2022. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF Amended and Restated CERTIFICATE OF INCORPORATION OF NANTHEALTH, INC. NantHealth, Inc., a Delaware corporation (the ?Corporation?), hereby certifies as follows: 1.The name of the Corporation is NantHealth, Inc. The Corporation was first formed on July 7, 2010 as ?About Advanced Health, LLC? in Delaware as a Limited Liability Company and was converted into Na
December 15, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2022 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
November 28, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 21, 2022 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
November 28, 2022	EX-10.1	Subordinated Promissory Note by and between the Company and Exhibit 10.1 SUBORDINATED PROMISSORY NOTE November 21, 2022 Morrisville, North Carolina 1.Principal and Interest. For value received, NantHealth, Inc., a Delaware corporation, with offices at 3000 RDU Drive, Suite 200 Morrisville, North Carolina 27560 (the ?Company?) promises to pay to the order of Nant Capital, LLC, a Delaware limited liability company, with offices at 450 Duley Road, El Segundo,
November 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantH
November 3, 2022	EX-99.1	NANTHEALTH REPORTS 2022 THIRD QUARTER FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2022 THIRD QUARTER FINANCIAL RESULTS ?Q3 2022 Financial and Operational Highlights: ?Total net revenue was $16.6 million ?Gross profit was $9.7 million, or 58% of total revenue ?The company?s Eviti Connect platform earned full URAC accreditation for Health Utilization Management, through 2025 ?Maryland
November 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2022 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File N
October 6, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 3, 2022 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Nu
October 6, 2022	EX-10.1	Subordinated Promissory Note by and between NantHealth, Inc. and AirStrip Technologies, Inc. dated as of October 3, 2022 Exhibit 10.1 SUBORDINATED PROMISSORY NOTE October 3, 2022 Culver City, California 1.Principal and Interest. For value received, NantHealth, Inc., a Delaware corporation, with offices at 3000 RDU Drive, Suite 200 Morrisville, North Carolina 27560 (the ?Company?) promises to pay to the order of Airstrip Technologies, Inc., a Delaware corporation, with officers at 2915 W. Bitters Road, Suite 215, San
September 7, 2022	DEFA14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement NantHealth, Inc. (Nam
August 24, 2022	DEF 14C	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 DEF 14C 1 a8182022def14c.htm DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION (Rule 14c-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Inform
August 19, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 18, 2022 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Nu
August 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantHealth
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2022 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Num
August 4, 2022	EX-99.1	NANTHEALTH REPORTS 2022 SECOND QUARTER FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2022 SECOND QUARTER FINANCIAL RESULTS ?Q2 2022 Financial and Operational Highlights: ?Total net revenue was $16.5 million ?Gross margin was 55% of total revenue ?NantHealth products won three industry awards, one from MedTech Breakthrough and two from Spring Digital Health Morrisville, NC ? August 4, 20
June 13, 2022	EX-3.1	Amended and Restated Bylaws Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF NANTHEALTH, INC. (as amended and restated on June 8, 2022) TABLE OF CONTENTS Page ARTICLE I ? CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II ? MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOCKHOLDERS? MEETINGS 6 2.6 QUORUM 6 2.7 ADJO
June 13, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 8, 2022 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Numbe
May 6, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantHealt
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2022 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Number
May 5, 2022	EX-99.1	NANTHEALTH REPORTS 2022 FIRST QUARTER FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2022 FIRST QUARTER FINANCIAL RESULTS •Q1 2022 Financial Highlights: •Total net revenue was $16.4 million •Gross margin was 56% of total revenue •Post Quarter End: •NaviNet Open Won MedTech Breakthrough “Healthcare Insurance Innovation Award.” This is the second year in a row that a NantHealth product ha
April 27, 2022	DEF 14A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 DEF 14A 1 a4182022def14a-definitivep.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permit
April 27, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini
February 25, 2022	EX-4.1	Description of Securities Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 NantHealth, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), our Common Stock. Description of Common Stock The following description of our Common Stock is a summary and does not purport
February 25, 2022	EX-21.1	NantHealth, Inc. Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom NantHealth Labs, Inc. Delaware NantHealth Singapore Pte Ltd Singapore New Nant Health Canada, Inc. Canada The Open NMS Group, Inc. Exhibit 21.1 NantHealth, Inc. Subsidiaries Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom NantHealth Labs, Inc. Delaware NantHealth Singapore Pte Ltd Singapore New Nant Health Canada, Inc. Canada The Open NMS Group, Inc. North Carolina OpenNMS Group Canada, Inc. Canada Note: Subsidiary companies excluded from the above listing, if considered i
February 25, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 18, 2022 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
February 25, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37792 NantHealth, In
February 25, 2022	EX-24.1	Power of Attorney (Contained on Signature Page to this Annual Report on Form 10-K). Exhibit 24.1 POWER OF ATTORNEY Each person whose signature appears below constitutes and appoints Patrick Soon-Shiong and Bob Petrou, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on
February 24, 2022	EX-99.1	NANTHEALTH REPORTS 2021 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2021 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS ?Q4 2021 Financial Highlights: ?Total revenue was $16.0 million ?Total gross margin was 57% ?Full-Year 2021 Financial Highlights: ?Total revenue was $62.6 million ?Total gross margin was 56% ?Operational Highlights: ?In Q4, signed and went live with Eviti
February 24, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2022 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
February 4, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 31, 2022 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File N
November 12, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2021 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
November 12, 2021	EX-10.1	dated November 12, 2021, by and between NantHealth, Inc. and Jefferies LLC OPEN MARKET SALE AGREEMENT1 November 12, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: NantHealth, Inc.
November 12, 2021	424B5	Up to $30,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-254937 PROSPECTUS SUPPLEMENT (To prospectus dated May 6, 2021) Up to $30,000,000 Common Stock We have entered into a certain Open Market Sale AgreementSM (the ?Sales Agreement?) with Jefferies LLC (?Jefferies?) relating to shares of our common stock, $0.0001 par value per share, offered by this prospectus supplement and the accompanying prospec
November 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantH
November 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2021 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File N
November 4, 2021	EX-99.1	NANTHEALTH REPORTS 2021 THIRD QUARTER FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2021 THIRD QUARTER FINANCIAL RESULTS ?Q3 2021 Financial Highlights: ?Total net revenue was $14.4 million ?Gross margin was 52% ?Cash of $45.5 million at September 30, 2021 ?Operational Highlights: ?Signed and preparing to launch first Eviti Connect program for autoimmune disease ?Achieved utilization ma
September 14, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 9, 2021 NantHealth, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 9, 2021 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
August 6, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantHealth
August 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2021 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Num
August 5, 2021	EX-99.1	NANTHEALTH REPORTS 2021 SECOND QUARTER FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2021 SECOND QUARTER FINANCIAL RESULTS ?Q2 2021 Financial Highlights: ?Total net revenue was $16.1 million ?Gross margin was 56% ?Completed $137.5 million financing transaction, extending maturity of debt and increasing cash position to $52 million at June 30 ?NaviNet AllPayer won Digital Health Award in
July 1, 2021	424B3	NantHealth, Inc. 25,337,835 Shares Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-256474 PROSPECTUS NantHealth, Inc. 25,337,835 Shares Common Stock This prospectus relates to the potential sale or disposition from time to time by the selling stockholders identified in this prospectus (collectively, the ?Selling Stockholders?) of some or all of the shares of our common stock, par value $0.0001 (?Common Stock?) issuable upon c
June 21, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Num
May 28, 2021	CORRESP	May 28, 2021 CORRESP 1 filename1.htm May 28, 2021 VIA EDGAR Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Anna Abramson Re: NantHealth, Inc. Registration Statement on Form S-3 Filed May 26, 2021 File No. 333-256474 Acceleration Request Requested Date: June 2, 2021 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant t
May 26, 2021	S-3	As filed with the Securities and Exchange Commission on May 25, 2021 Registration No. 333- As filed with the Securities and Exchange Commission on May 25, 2021 Registration No.
May 18, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2021 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Numbe
May 7, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantHealt
May 6, 2021	EX-99.1	NANTHEALTH REPORTS 2021 FIRST QUARTER FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2021 FIRST QUARTER FINANCIAL RESULTS ?Q1 2021 Financial Highlights: ?Total net revenue was $16.2 million, nearly all of which was software-related revenue ?Gross margin was 56% of total revenue ?Post Quarter End: ?Completed $137.5 million in new financing ?Launched Eviti? Connect for autoimmune diseases
May 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2021 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Number
May 4, 2021	CORRESP	May 4, 2021 May 4, 2021 VIA EDGAR Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Edwin Kim Re: NantHealth, Inc. Registration Statement on Form S-3 Filed March 31, 2021 File No. 333-254937 Acceleration Request Requested Date: May 6, 2021 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securit
April 29, 2021	DEF 14A	- DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
April 28, 2021	EX-10.3	Resale Registration Rights Agreement, dated April 27, 2021, by and among NantHealth, Inc. and certain buyers. Exhibit 10.3 EXECUTION VERSION NANTHEALTH, INC. RESALE REGISTRATION RIGHTS AGREEMENT April 27, 2021 TABLE OF CONTENTS Page Section 1 Definitions 1 1.1 Certain Definitions 1 Section 2 Registration Rights 3 2.1 Registration 3 2.2 Expenses of Registration 5 2.3 Registration Procedures 5 2.4 Information by the Holder 8 2.5 Reserved 8 2.6 Rule 144 Reporting 8 2.7 Transfer or Assignment of Registration
April 28, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 27, 2021 NantHealth, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation or organization) (Co
April 28, 2021	EX-10.2	Second Amended and Restated Promissory Note, dated April 27, 2021, by and between NantHealth, Inc. and Nant Capital LLC Exhibit 10.2 SECOND AMENDED AND RESTATED PROMISSORY NOTE Up to $125,000,000 April 27, 2021 Culver City, California WHEREAS, NantHealth, Inc., a Delaware corporation, with offices at 9920 Jefferson Boulevard, Culver City, California 90232 (the ?Company?), entered into a promissory note dated August 8, 2018 (the ?Original Note?) in favor of Nant Capital, LLC, with offices at 9922 Jefferson Boulevard
April 28, 2021	EX-4.1	Indenture, dated April 27, 2021, among NantHealth, Inc., NaviNet, Inc. and U.S. Bank National Association. Exhibit 4.1 NANTHEALTH, INC. as Issuer NAVINET, INC. As Guarantor AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of April 27, 2021 4.50% Convertible Senior Notes due 2026 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 2 Section 1.01 Definitions 2 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES 15 Section 2.01 Designation and Amount 15 Section 2.02 Form
April 28, 2021	EX-10.1	Third Amended and Restated Promissory Note, dated April 27, 2021, by and between NantHealth, Inc. and Nant Capital LLC Exhibit 10.1 THIRD AMENDED AND RESTATED PROMISSORY NOTE April 27, 2021 Culver City, California WHEREAS, NantHealth, Inc. (formerly Nant Health, LLC), a Delaware corporation, with offices at 9920 Jefferson Boulevard, Culver City, California 90232 (the ?Company?), entered into a demand promissory note dated January 4, 2016 (the ?Original Note?) in favor of Nant Capital, LLC, with offices at 9922 Jef
April 14, 2021	EX-10.2	Form of Exchange Agreement by and between the Company and Cambridge Equities, L.P., dated as of April 13, 2021 EX-10.2 3 exhibit102-exchangeagreeme.htm EX-10.2 Exhibit 10.2 EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”), dated as of April 13, 2021, is by and between NantHealth, Inc., a Delaware corporation (the “Company”), and the undersigned holder (the “Holder”) of certain of the Company’s 5.50% Convertible Senior Notes due December 15, 2021 (the “Notes”). WHEREAS, the Holder will exchange
April 14, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events 8-K 1 a8-k4132021.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 13, 2021 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorpora
April 14, 2021	EX-10.1	Form of Exchange Agreement by and between the Company and certain holders, dated as of April 13, 2021 EX-10.1 2 exhibit101-exchangeagreeme.htm EX-10.1 Exhibit 10.1 EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”), dated as of April 13, 2021, is by and between NantHealth, Inc., a Delaware corporation (the “Company”), and the undersigned holders (the “Holders”) of certain of the Company’s 5.50% Convertible Senior Notes due December 15, 2021 (CUSIP 630104 AB3) (the “Notes”). WHEREAS, the
April 14, 2021	EX-10.3	Note Purchase Agreement by and among the Company, NaviNet, Inc., and certain buyers, dated as of April 13, 2021 Exhibit 10.3 NOTE PURCHASE AGREEMENT This Note Purchase Agreement (the ?Agreement?), dated as of April 13, 2021, is by and among NantHealth, Inc., a Delaware corporation (the ?Company?), NaviNet, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (the ?Guarantor?), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a ?Buyer? and collectiv
April 14, 2021	EX-99.1	NANTHEALTH ANNOUNCES $137.5 MILLION NEW FINANCING WITH HIGHBRIDGE CAPITAL MANAGEMENT AND NANT CAPITAL Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH ANNOUNCES $137.5 MILLION NEW FINANCING WITH HIGHBRIDGE CAPITAL MANAGEMENT AND NANT CAPITAL ?Transaction proceeds to be used to retire NantHealth?s existing convertible notes due in 2021, invest in established businesses, and accelerate growth initiatives including NantHealth?s continued expansion of SaaS offeri
March 31, 2021	EX-4.11	Form of Indenture. Exhibit 4.11 NANTHEALTH, INC. INDENTURE Dated as of , 20 U.S. BANK NATIONAL ASSOCIATION Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 2 Section 1.1 Definitions 2 Section 1.2 Other Definitions 6 Section 1.3 Incorporation by Reference of Trust Indenture Act 6 Section 1.4 Rules of Construction 6 ARTICLE II THE SECURITIES 7 Section 2.1 Issuable in Series 7 Section
March 31, 2021	S-3	- S-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S?3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NANTHEALTH, INC. (Exact name of Registrant as specified in its charter) Delaware 27-3019889 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 9920 Jefferson Blvd Culver City, California 90232 (Address of principal executive offic
February 26, 2021	EX-24.1	Power of Attorney (Contained on Signature Page to this Annual Report on Form 10-K). Exhibit 24.1 POWER OF ATTORNEY Each person whose signature appears below constitutes and appoints Patrick Soon-Shiong and Bob Petrou, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on
February 26, 2021	EX-21.1	NantHealth, Inc. Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom NantHealth Labs, Inc. Delaware NantHealth Singapore Pte Ltd Singapore New Nant Health Canada, Inc. Canada The Open NMS Group, Inc. Exhibit 21.1 NantHealth, Inc. Subsidiaries Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom NantHealth Labs, Inc. Delaware NantHealth Singapore Pte Ltd Singapore New Nant Health Canada, Inc. Canada The Open NMS Group, Inc. North Carolina OpenNMS Group Canada, Inc. Canada Note: Subsidiary companies excluded from the above listing, if considered i
February 26, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37792 NantHealth, In
February 26, 2021	EX-4.1	Description of Securities Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 NantHealth, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), our Common Stock. Description of Common Stock The following description of our Common Stock is a summary and does not purport
February 25, 2021	EX-99.1	NANTHEALTH REPORTS 2020 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS EX-99.1 2 a99112312020ng.htm EX-99.1 Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2020 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS •Q4 Financial Highlights 2020 vs 2019: ◦Total revenue was $18.6 million •Total software-related revenue was $18.6 million, up from $18.4 million ◦Total gross margin increased to 61% from 58% •Full-Year Financial Highli
February 25, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 25, 2021 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
January 5, 2021	EX-10.1	Amended and Restated Promissory Note by and between the Company and Nant Capital, LLC dated as of December 31, 2020 EX-10.1 2 exhibit1012020-12x29xxprom.htm EX-10.1 Exhibit 10.1 AMENDED AND RESTATED PROMISSORY NOTE Up to $125,000,000 December 31, 2020 Culver City, California WHEREAS, NantHealth, Inc., a Delaware corporation, with offices at 9920 Jefferson Boulevard, Culver City, California 90232 (the “Company”), entered into a promissory note dated August 8, 2018 (the “Original Note”) in favor of Nant Capital,
January 5, 2021	EX-10.2	Amendment No. 3 to Second Amended and Restated NantOmics Exclusive Reseller Agreement dated as of December 31, 2020. Exhibit 10.2 AMENDMENT NO. 3 TO SECOND AMENDED AND RESTATED NANTOMICS EXCLUSIVE RESELLER AGREEMENT This Amendment No. 3 (the "Amendment") is made as of December 31, 2020 (the “Amendment Effective Date”), by and between NantHealth, Inc. (“NantHealth”) and NantOmics, LLC (“NantOmics”). RECITALS Whereas, NantHealth and NantOmics are parties to that certain Second Amended and Restated NantOmics Exclus
January 5, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2020 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
November 9, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantH
November 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a8-k09302020.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 5, 2020 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorp
November 5, 2020	EX-99.1	NANTHEALTH REPORTS 2020 THIRD QUARTER FINANCIAL RESULTS EX-99.1 2 exhibit99109302020.htm EX-99.1 Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2020 THIRD QUARTER FINANCIAL RESULTS •Q3 2020 Financial Highlights: •Total net revenue was $18.8 million, up from $18.6 million •Total software-related revenue increased to $18.7 million from $18.3 million in Q3 2019 and rose 7% from Q2 2020 •Recently acquired Op
August 10, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantHealth,
August 10, 2020	EX-10.1	Open NMS Assignment Agreement, dated as of July 22, 2020, between the Registrant and Cambridge Equities, LP. OpenNMS ASSIGNMENT AGREEMENT This OpenNMS Assignment Agreement (this “Agreement”), dated as of July 22, 2020, is by and between Cambridge Equities, LP, a Delaware limited partnership (“Cambridge), and NantHealth, Inc.
August 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 6, 2020 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Num
August 6, 2020	EX-99.1	NANTHEALTH REPORTS 2020 SECOND QUARTER FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2020 SECOND QUARTER FINANCIAL RESULTS • Q2 Financial Highlights 2020 vs 2019: • SaaS revenue of $17.5 million vs $18.3 million • Total gross margin of 58%, up from 56% • In July 2020, acquired OpenNMS Group, the world’s premier open source network management company • Expands product and service offerin
July 27, 2020	EX-99.1	NantHealth Acquires OpenNMS, the World’s Largest Open Source Network Management Application Platform Exhibit 99.1 NantHealth Acquires OpenNMS, the World’s Largest Open Source Network Management Application Platform CULVER CITY, CA - July 27, 2020 - NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced the acquisition of The OpenNMS Group, Inc. (www.opennms.com), the world’s premier open-source network management company, which will oper
July 27, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 22, 2020 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Numb
June 19, 2020	S-8	- S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NantHealth, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9920 Jefferson Blvd Culver City, California 90232 (A
June 19, 2020	EX-24.1	Power of Attorney (contained on signature page hereto). Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Patrick Soon-Shiong, M.D. and Bob Petrou, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities,
June 19, 2020	EX-99.1	2016 Equity Incentive Plan Exhibit 99.1 NANTHEALTH, INC. 2016 EQUITY INCENTIVE PLAN (As Amended and Restated May 21, 2020) 1.Purposes of the Plan. The purposes of this Plan are: •to attract and retain the best available personnel for positions of substantial responsibility, •to provide additional incentive to Employees, Directors and Consultants, and •to promote the success of the Company’s business. The Plan permits the gr
May 29, 2020	EX-1.01	NantHealth, Inc. Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 NantHealth, Inc. Conflict Minerals Report For The Year Ended December 31, 2019 Cautionary Note Concerning Forward-Looking Statements: This Conflict Minerals Report contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements include statements concerning NantHealth’s objectives for its conflict minerals policy and compliance initi
May 29, 2020	SD	- SD SD 1 sd5292020.htm SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 9920 Jefferson Blvd Culver City, California 90232 (Addres
May 22, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Numb
May 8, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantHealt
May 7, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2020 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Number
May 7, 2020	EX-99.1	NANTHEALTH REPORTS 2020 FIRST QUARTER FINANCIAL RESULTS EX-99.1 2 exhibit99103312020.htm EXHIBIT 99.1 Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2020 FIRST QUARTER FINANCIAL RESULTS • Q1 Financial Highlights 2020 vs 2019: • SaaS revenue was $18.1 million, up 2% • Total gross margin increased to 60% from 49% • Appointed Deanna L. Wise, Senior Vice President and Chief Information Officer for Banner Hea
April 21, 2020	DEF 14A	NH / NantHealth, Inc. DEF 14A - - DEF 14A DEF 14A 1 d865528ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as
March 16, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2020 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Num
March 16, 2020	EX-99.1	NANTHEALTH ANNOUNCES APPOINTMENT OF DEANNA L. WISE TO ITS BOARD OF DIRECTORS New board member brings clinical expertise and IT leadership Exhibit 99.1 NANTHEALTH ANNOUNCES APPOINTMENT OF DEANNA L. WISE TO ITS BOARD OF DIRECTORS New board member brings clinical expertise and IT leadership Culver City, CA - March 12, 2020 - NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced today the appointment of Deanna L. Wise, Senior Vice President and Chief Information Officer for Banner H
February 28, 2020	10-K	NH / NantHealth, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37792 NantHealth, In
February 28, 2020	EX-99.1	NANTHEALTH REPORTS 2019 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2019 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS • Q4 Financial Highlights 2019 vs 2018: ◦ Total revenue was $24.2 million, up 6% ◦ SaaS revenue was $18.4 million, up 6% ◦ Total gross margin increased to 63% from 50% • Full-Year Financial Highlights 2019 vs 2018: ◦ Total revenue was $96.0 million, up 7%
February 28, 2020	EX-24.1	Power of Attorney (Contained on Signature Page to this Annual Report on Form 10-K). Exhibit 24.1 POWER OF ATTORNEY Each person whose signature appears below constitutes and appoints Patrick Soon-Shiong and Bob Petrou, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on
February 28, 2020	EX-4.1	Description of Securities Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 NantHealth, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our Common Stock. Description of Common Stock The following description of our Common Stock is a summary and does not purport
February 28, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2020 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
February 28, 2020	EX-21.1	NantHealth, Inc. Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom Assisteo Holding, Inc. Delaware AZ Home Health, LLC Delaware NantHealth Labs, Inc. Delaware NantHealth Singapore Pte Ltd Singapore Exhibit 21.1 NantHealth, Inc. Subsidiaries Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom Assisteo Holding, Inc. Delaware AZ Home Health, LLC Delaware NantHealth Labs, Inc. Delaware NantHealth Singapore Pte Ltd Singapore New Nant Health Canada, Inc. Canada Note: Subsidiary companies excluded from the above listing, if considered in the aggrega
February 28, 2020	EX-2.1	Asset Purchase Agreement dated as of January 13, 2020, among Masimo Corporation and VCCB Holdings, Inc., and NantHealth, Inc. Exhibit 2.1 ASSET PURCHASE AGREEMENT BY AND AMONG MASIMO CORPORATION AND VCCB Holdings, Inc., AS PURCHASER, NANTHEALTH, INC., AS SELLER AND SOLELY WITH RESPECT TO SECTION 4.26, SECTION 6.07, ARTICLE X AND ARTICLE XI, NANTWORKS, LLC January 13, 2020 Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material and (ii
February 6, 2020	8-K	Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 3, 2020 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File N
February 6, 2020	EX-99.1	NantHealth, Inc. Summary of Unaudited Pro Forma Financial Information (Dollars in thousands, except per share amounts) EX-99.1 2 exhibit99102062020.htm EXHIBIT 99.1 02.06.2020 Exhibit 99.1 NantHealth, Inc. Summary of Unaudited Pro Forma Financial Information (Dollars in thousands, except per share amounts) Overview On January 13, 2020, NantHealth, Inc., a Delaware corporation (the “Company”), entered into an asset purchase agreement (the “Purchase Agreement”) with Masimo Corporation (“Masimo”), VCCB Holdings, Inc.
January 14, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2020 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File N
January 14, 2020	EX-99.1	Masimo to Acquire Connected Care Business from NantHealth Exhibit 99.1 Masimo to Acquire Connected Care Business from NantHealth Irvine and Culver City, California - January 14, 2020 - Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies, and NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced the signing of a definitive agreement under which Masimo will acquire the C
November 7, 2019	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 a8-k1172019.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2019 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorpo
November 7, 2019	10-Q	NH / NantHealth, Inc. 10-Q - Quarterly Report - 10-Q 9.30.2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantH
November 7, 2019	EX-99.1	NANTHEALTH REPORTS 2019 THIRD-QUARTER FINANCIAL RESULTS EX-99.1 2 a99109302019.htm EXHIBIT 99.1 Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2019 THIRD-QUARTER FINANCIAL RESULTS • Q3 Financial Highlights: ◦ Total revenue was $22.4 million ◦ SaaS revenue was $18.3 million, up 15% from Q3 2018 ◦ Total gross margin increased to 63% from 50% in Q3 2018 ◦ Company was cash flow positive, with cash growing by
November 7, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2019 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File N
August 13, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2019 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Num
August 8, 2019	EX-99.1	NANTHEALTH REPORTS 2019 SECOND-QUARTER FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2019 SECOND-QUARTER FINANCIAL RESULTS • Q2 Financial Highlights: ◦ Fourth consecutive quarter of total revenue growth ◦ Total revenue was $25.7 million, up 17% from Q2 2018 ◦ SaaS revenue of $18.3 million, rose 13% from Q2 2018 and 3% sequentially ◦ Gross profit was $15.9 million, compared with $11.5 mi
August 8, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a8k06302019.htm 8-K 06.30.2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2019 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction o
August 8, 2019	10-Q	NH / NantHealth, Inc. 10-Q - Quarterly Report - 10-Q 06.30.2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantHealth
June 28, 2019	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2019 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Numb
June 17, 2019	8-K	Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2019 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Num
May 31, 2019	SD	NH / NantHealth, Inc. SD - - SD 5.31.2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation (Commission File Number) (I.R.S. Employer Identification No.) 9920 Jefferson Blvd Culver City, California 90232 (Address of principal executiv
May 31, 2019	EX-1.01	NantHealth, Inc. Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. EX-1.01 2 a1015312019.htm EXHIBIT 1.01 5.31.2019 Exhibit 1.01 NantHealth, Inc. Conflict Minerals Report For The Year Ended December 31, 2018 Cautionary Note Concerning Forward-Looking Statements: This Conflict Minerals Report contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements include statements concerning NantHealth’s objectives for
May 9, 2019	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2019 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Number
May 9, 2019	EX-99.1	NANTHEALTH REPORTS 2019 FIRST-QUARTER FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2019 FIRST-QUARTER FINANCIAL RESULTS • Total revenue in Q1 was $23.7 million, up 7% from Q1 2018 ◦ SaaS revenue of $17.8 million in Q1, up 10% from Q1 2018 and 3% sequentially • Signed Substantial Three-year Eviti Contract with Multi-state Healthcare Payer • Sequencing and Molecular Analysis, 820 total
May 9, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2019 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Number
May 9, 2019	10-Q	NH / NantHealth, Inc. 10-Q Quarterly Report 10-Q 03.31.2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantHealt
May 9, 2019	EX-10.1	Amendment No. 2 to Second Amended and Restated NantOmics Exclusive Reseller Agreement, dated as of April 23, 2019, by and between the Registrant and NantOmics, LLC. Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]” AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED NANTOMICS EXCLUSIVE RESELLER AGREEMENT This Amen
April 30, 2019	DEF 14A	NH / NantHealth, Inc. DEF 14A DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 2, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2019 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Nu
April 1, 2019	10-K	NH / NantHealth, Inc. 10-K 12.31.2018 (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37792 NantHealth, In
April 1, 2019	EX-24.1	Power of Attorney (Contained on Signature Page to this Annual Report on Form 10-K). Exhibit 24.1 POWER OF ATTORNEY Each person whose signature appears below constitutes and appoints Patrick Soon-Shiong and Bob Petrou, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on
April 1, 2019	EX-21.1	NantHealth, Inc. Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom Assisteo Holding, Inc. Delaware AZ Home Health, LLC Delaware NantHealth Labs, Inc. Delaware NantHealth Singapore Pte Ltd Singapore Exhibit 21.1 NantHealth, Inc. Subsidiaries Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom Assisteo Holding, Inc. Delaware AZ Home Health, LLC Delaware NantHealth Labs, Inc. Delaware NantHealth Singapore Pte Ltd Singapore New Nant Health Canada, Inc. Canada Note: Subsidiary companies excluded from the above listing, if considered in the aggrega
March 28, 2019	EX-99.1	NANTHEALTH REPORTS 2018 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2018 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS • Total Revenue in Q4 was $22.9 Million ◦ SaaS revenue of $17.3 million in Q4, up 9% from Q3 • Enhanced efficiencies continued to drive significantly lower operating expenses in both Q4 and full year of 2018 • For 2018, substantially improved adjusted Non
March 28, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 28, 2019 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Num
March 18, 2019	NT 10-K	NH / NantHealth, Inc. NT 10-K 3.18.2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) x Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on
January 18, 2019	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 16, 2019 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File N
November 21, 2018	10-Q	NH / NantHealth, Inc. 10-Q 09.30.2018 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantH
November 21, 2018	EX-10.2	Amended and Restated Consulting Agreement dated September 12, 2018, between the Company and Mr. Bob Petrou AMENDED AND RESTATED CONSULTING AGREEMENT This Amended and Restated Consulting Agreement (this “Agreement”) is made and entered into as of September 12, 2018 (the “Effective Date”) by and between Bob Petrou (“Consultant”) and NantHealth, Inc.
November 21, 2018	EX-10.3	Transition Agreement and Release dated September 11, 2018, between the Company and Mr. Paul Holt TRANSITION AGREEMENT AND RELEASE This Transition Agreement and Release (this “Agreement”) is made and entered into as of August 23, 2018 (the “Effective Date”) by and between Paul Holt (“Employee”) and NantHealth, Inc.
November 15, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2018 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
November 15, 2018	EX-99.1	NANTHEALTH REPORTS 2018 THIRD-QUARTER FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2018 THIRD-QUARTER FINANCIAL RESULTS • Total Revenue in Q3 was $22.3 Million ◦ SaaS revenue of $15.9 million in Q3, up 5% from $15.2 million in prior year Q3 ◦ Enhanced efficiencies continued to drive reduced operating expenses and improved adjusted bottom line results • Sequencing and Molecular Analysi
September 12, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2018 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commis
August 23, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2018 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission Fi
August 9, 2018	EX-10.1	Promissory note dated August 8, 2018, by the Company to the benefit of Nant Capital, LLC. PROMISSORY NOTE Up to $100,000,000 August 8, 2018 Culver City, California For value received, NantHealth, Inc.
August 9, 2018	10-Q	NH / NantHealth, Inc. 10-Q 06.30.2018 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantHealth
August 9, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 9, 2018 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Num
August 9, 2018	EX-99.1	NANTHEALTH REPORTS 2018 SECOND-QUARTER FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2018 SECOND-QUARTER FINANCIAL RESULTS • Liquid GPS® Successfully Launched in Q2 • Total Revenue in Q2 was $22.0 Million ◦ Revenue in 2017 Q2 included a large completed Connected Care device implementation of approximately $4 million, benefiting prior period revenue of $23.5 million ◦ SaaS revenue of $16
July 11, 2018	EX-10.1	Assignment Agreement, dated February 1, 2018, by and between the Company and NantOmics, LLC. EX-10.1 Exhibit 10.1 ASSIGNMENT AGREEMENT This Assignment Agreement (this “Agreement”), dated as of February 1, 2018 (the “Effective Date”), is between NantOmics, LLC (“NantOmics), a Delaware limited liability company, and NantHealth, Inc., a Delaware corporation (“NantHealth”). NantOmics and NantHealth are each sometimes referred to herein as a “Party” and collectively as “Parties.” RECITALS WHER
July 11, 2018	10-Q/A	NH / NantHealth, Inc. 10-Q/A (Quarterly Report) 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file
June 15, 2018	S-8	NH / NantHealth, Inc. S-8 S-8 1 d580324ds8.htm S-8 As filed with the Securities and Exchange Commission on June 15, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NantHealth, Inc. (Exact name of Registrant as specified in its charter) Delaware 27-3019889 (State or other jurisdiction of incorporation or organ
June 11, 2018	EX-10.1	2016 Equity Incentive Plan, as Amended and Restated, and related form agreements (which is incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37792), filed with the Commission on June 11, 2018). EX-10.1 Exhibit 10.1 NANTHEALTH, INC. 2016 EQUITY INCENTIVE PLAN (As Amended and Restated June 8, 2018) 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan pe
June 11, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2018 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
May 10, 2018	EX-10.1	Assignment Agreement, dated February 1, 2018, by and between the Company and NantOmics, LLC. Exhibit 10.1 CONFIDENTIAL CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION THAT WAS OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. ASSIGNMENT AGREEMENT This Assignment Agreement (this “Agreement”), dated a
May 10, 2018	10-Q	NH / NantHealth, Inc. 10-Q 3.31.2018 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantHealt
May 9, 2018	EX-99.1	NANTHEALTH REPORTS 2018 FIRST-QUARTER FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2018 FIRST-QUARTER FINANCIAL RESULTS • Total Q1 Revenue of $22.3 Million, Up 17% from $19.1 Million in Prior Year Q1 •SAAS Revenue of $16.2 Million in Q1, Up 9% from $14.8 Million in Prior Year Q1 • Total Gross Margin increased to 50% in Q1, Up from 40% in Prior Year Q1 • Study Results Demonstrating Ben
May 9, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2018 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Number
April 30, 2018	DEF 14A	NH / NantHealth, Inc. DEF 14A DEF 14A 1 d545562ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as
April 2, 2018	CORRESP	NH / NantHealth, Inc. CORRESP CORRESP April 2, 2018 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Edwin Kim, Attorney-Advisor Re: NantHealth, Inc. Registration Statement on Form S-3 Filed March 16, 2018 File No. 333-223744 Acceleration Request Requested Date: April 4, 2018 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: Pursua
March 16, 2018	EX-4.11	Form of Senior Indenture. EX-4.11 Exhibit 4.11 NANTHEALTH, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions 1 Section 1.2 Compliance Certificates and Opinions 8 Section 1.3 Form of Documents Delivered to Trustee 9 Section 1.4 Acts of Holders; Record Dates 9 Section 1.5 Notices, etc., to Tru
March 16, 2018	EX-12.1	Statement re Computation of Ratio of Earnings to Fixed Charges and Preference Dividends. EX-12.1 Exhibit 12.1 NantHealth, Inc. Ratio of Earnings to Fixed Charges and Preference Dividends Years Ended December 31, (in thousands) 2017 2016 2015 2014 Loss from continuing operations and discontinued operations, before taxes $ (170,523 ) $ (206,913 ) $ (71,606 ) $ (84,612 ) Add: Fixed charges 17,699 8,467 2,144 2,400 Total Loss (152,824 ) (198,446 ) (69,462 ) (82,212 ) Fixed charges calcula
March 16, 2018	S-3	NH / NantHealth, Inc. FORM S-3 S-3 1 d551712ds3.htm FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on March 16, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 NANTHEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 27-3019889 (State or other jurisdiction o
March 16, 2018	EX-4.13	Form of Subordinated Indenture. EX-4.13 3 d551712dex413.htm EX-4.13 Exhibit 4.13 NANTHEALTH, INC. TO AS TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions 1 Section 1.2 Compliance Certificates and Opinions 10 Section 1.3 Form of Documents Delivered to Trustee 11 Section 1.4 Acts of Holders; Record Dates
March 16, 2018	EX-21.1	NantHealth, Inc. Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom Assisteo Holding, Inc. Delaware AZ Home Health, LLC Delaware NantHealth Singapore Pte Ltd Singapore New Nant Health Canada, Inc. Ca Exhibit 21.1 NantHealth, Inc. Subsidiaries Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom Assisteo Holding, Inc. Delaware AZ Home Health, LLC Delaware NantHealth Singapore Pte Ltd Singapore New Nant Health Canada, Inc. Canada Note: Subsidiary companies excluded from the above listing, if considered in the aggregate, would not constitute a sign
March 16, 2018	10-K	NH / NantHealth, Inc. 10-K 12.31.2017 (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37792 NantHealth, In
March 16, 2018	EX-10.14	Amendment No.1 to Second Amended and Restated Reseller Agreement, dated December 18, 2017, by and between NantHealth, Inc. and NantOmics, LLC. Exhibit 10.14 CONFIDENTIAL CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION THAT WAS OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED NANTOMICS EXCLUSIVE RESELL
March 16, 2018	EX-24.1	Power of Attorney (Contained on Signature Page to this Annual Report on Form 10-K). Exhibit 24.1 POWER OF ATTORNEY Each person whose signature appears below constitutes and appoints Patrick Soon-Shiong and Paul Holt, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on
March 14, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 14, 2018 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File Num
March 14, 2018	EX-99.1	NANTHEALTH REPORTS 2017 FOURTH-QUARTER AND FULL-YEAR FINANCIAL RESULTS Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2017 FOURTH-QUARTER AND FULL-YEAR FINANCIAL RESULTS • Total Q4 Revenue of $22.3 Million, Up 25% from $17.8 Million in Prior Year Q4 • SAAS Revenue of $15.8 Million in Q4, Up 10% from $14.4 Million in Prior Year Q4 • Total Gross Margin increased to 60% in Q4, Up from 39% in Prior Year Q4 • Restructuring
March 9, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2018 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission
February 14, 2018	EX-99.1	JOINT FILING AGREEMENT EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of NantHealth, Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended. Date: Fe
February 14, 2018	SC 13G/A	NH / NantHealth, Inc. / CALIFORNIA CAPITAL EQUITY, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NantHealth, Inc. (Name of Issuer) Common Stock, Par value $0.0001 per share (Title of Class of Securities) 630104107 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
November 14, 2017	10-Q	NH / NantHealth, Inc. 10-Q 09.30.2017 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantH
November 9, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2017 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commissi
November 9, 2017	EX-99.1	NANTHEALTH REPORTS 2017 THIRD QUARTER FINANCIAL RESULTS; GPS REVENUE DOUBLES FROM PRECEDING QUARTER Exhibit Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2017 THIRD QUARTER FINANCIAL RESULTS; GPS REVENUE DOUBLES FROM PRECEDING QUARTER ? GPS Revenue Exceeds $1.0 Million in Q3, Up 128% from Q2 ? 547 GPS Commercial Tests Ordered in Q3, Up 44% from Q2 ? 204 GPS Tests Ordered in October, Largest Month of Orders to Date ? Signed New International Resel
August 31, 2017	8-K	Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 25, 2017 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commissio
August 31, 2017	EX-2.1	Asset Purchase Agreement dated as of August 3, 2017, between Allscripts Healthcare Solutions, Inc. and NantHealth Inc. Exhibit Exhibit 2.1 CONFIDENTIAL ASSET PURCHASE AGREEMENT Dated as of August 3, 2017 Between Allscripts Healthcare Solutions, Inc. and NantHealth, Inc. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INTERPRETATIONS 1 1.1 Definitions 1 1.2 Interpretation 13 ARTICLE II PURCHASE AND SALE 13 2.1 Purchased Assets 13 2.2 Excluded Assets 15 2.3 Assumed Liabilities 16 2.4 Excluded Liabilities 17 ARTICLE
August 31, 2017	EX-99.1	NantHealth, Inc. Summary of Unaudited Pro Forma Financial Information (Dollars in thousands, except per share amounts) EX-99.1 3 a99108252017.htm EXHIBIT 99.1 Exhibit 99.1 NantHealth, Inc. Summary of Unaudited Pro Forma Financial Information (Dollars in thousands, except per share amounts) Overview On August 3, 2017, NantHealth, Inc. ("the Company”) entered into an asset purchase agreement (the “APA”) with Allscripts Healthcare Solutions, Inc. (“Allscripts”), pursuant to which the Company agreed to sell to Allscri
August 11, 2017	10-Q	NH / NantHealth, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792 NantHealth
August 10, 2017	EX-99.1	NANTHEALTH REPORTS 2017 SECOND QUARTER FINANCIAL RESULTS; IMPLEMENTS PLAN TO FOCUS ON CORE COMPETENCIES, ENHANCE PROFITABILITY AND POSITION FOR GROWTH OF ARTIFICIAL INTELLIGENCE FOR CANCER CARE Exhibit Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 2017 SECOND QUARTER FINANCIAL RESULTS; IMPLEMENTS PLAN TO FOCUS ON CORE COMPETENCIES, ENHANCE PROFITABILITY AND POSITION FOR GROWTH OF ARTIFICIAL INTELLIGENCE FOR CANCER CARE ? Restructuring Plan Implemented To Focus on Cancer Decision Support and Artificial Intelligence Platform ? Integration o
August 10, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2017 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commissio
August 9, 2017	8-K	Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2017 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commissio
July 31, 2017	CORRESP	NantHealth ESP Document July 31, 2017 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
June 14, 2017	8-K	Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2017 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission File
May 22, 2017	EX-24	EX-24 Exhibit 24 POWER OF ATTORNEY The undersigned, as a Section 16 reporting person of NantHealth, Inc.
May 12, 2017	10-Q	NantHealth 10-Q (Quarterly Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37792
May 10, 2017	EX-99.1	NANTHEALTH REPORTS 16% INCREASE IN 2017 FIRST QUARTER TOTAL NET REVENUE; SAAS REVENUE ROSE 11% AND GPS ADOPTION CONTINUES TO CLIMB Exhibit Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 16% INCREASE IN 2017 FIRST QUARTER TOTAL NET REVENUE; SAAS REVENUE ROSE 11% AND GPS ADOPTION CONTINUES TO CLIMB ? GPS Adoption: ? GPS Cancer Test to Be Complementary Diagnostic for FDA Authorized Nant Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherap
May 10, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 10, 2017 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission F
April 24, 2017	DEF 14A	NantHealth DEF 14A Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Pr
March 31, 2017	10-K	NantHealth 10-K (Annual Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number: 001-37792 NantH
March 31, 2017	EX-21.1	NantHealth, Inc. Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom Assisteo Holding, Inc. Delaware AZ Home Health, LLC Delaware NantHealth Technologies India Private Ltd India NantHealth Ltd United Exhibit 21.1 NantHealth, Inc. Subsidiaries Name of Subsidiary Jurisdiction of Organization NaviNet, Inc. Delaware NaviNet Limited United Kingdom Assisteo Holding, Inc. Delaware AZ Home Health, LLC Delaware NantHealth Technologies India Private Ltd India NantHealth Ltd United Kingdom NantHealth Singapore Pte Ltd Singapore Nant Health Canada, Inc. Canada Net. Orange, Ltd United Kingdom Note: Subsidi
March 30, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 30, 2017 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission
March 30, 2017	EX-99.1	NANTHEALTH REPORTS 72% INCREASE IN FULL YEAR 2016 TOTAL NET REVENUE TO $100 MILLION WITH SAAS REVENUE INCREASING MORE THAN 181% AND INCREASING GPS CANCER ADOPTION EX-99.1 2 a99112312016.htm EXHIBIT 99.1 Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 72% INCREASE IN FULL YEAR 2016 TOTAL NET REVENUE TO $100 MILLION WITH SAAS REVENUE INCREASING MORE THAN 181% AND INCREASING GPS CANCER ADOPTION • GPS Cancer Adoption by Oncologists Increased in Q4: 264 Oncologists Ordered 1,286 GPS Commercial & Research Tests YTD,
February 14, 2017	SC 13G/A	NH / NantHealth, Inc. / KUWAIT INVESTMENT AUTHORITY ON BEHALF OF THE GOVT OF KUWAIT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nant Health, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Titles of Class of Securities) 630104107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul
February 13, 2017	EX-99.1	JOINT FILING AGREEMENT EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of NantHealth, Inc. is, and any amendment thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended. Date: Fe
February 13, 2017	SC 13G	NH / NantHealth, Inc. / CALIFORNIA CAPITAL EQUITY, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NantHealth, Inc. (Name of Issuer) Common Stock, Par value $0.0001 per share (Title of Class of Securities) 630104107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
December 21, 2016	EX-99.1	NantHealth, Inc. Announces Proposed $100 Million Convertible Notes Offering EX-99.1 Exhibit 99.1 NantHealth, Inc. Announces Proposed $100 Million Convertible Notes Offering Culver City, California ? December 15, 2016 ? NantHealth, Inc. (Nasdaq: NH) today announced its intention to offer, subject to market conditions and other factors, $100 million aggregate principal amount of convertible senior notes due 2021 (the ?notes?) in a private placement to qualified institutiona
December 21, 2016	EX-10.1	Purchase Agreement, dated December 15, 2016, by and among NantHealth, Inc. and J.P. Morgan Securities LLC and Jefferies LLC, as representative of the initial purchasers named therein. EX-10.1 Exhibit 10.1 NANTHEALTH, INC. 5.50% Convertible Senior Notes due 2021 Purchase Agreement December 15, 2016 J.P. MORGAN SECURITIES LLC JEFFERIES LLC As Representatives of the several Initial Purchasers listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Nant
December 21, 2016	EX-99.2	NantHealth, Inc. Announces Pricing of $100 Million of 5.50% Convertible Notes EX-99.2 Exhibit 99.2 NantHealth, Inc. Announces Pricing of $100 Million of 5.50% Convertible Notes Culver City, California ? December 16, 2016 ? NantHealth, Inc. (Nasdaq: NH) today announced the pricing of an aggregate of $100 million principal amount of 5.50% Convertible Senior Notes due 2021 (the ?Notes?), in a private offering to qualified institutional buyers pursuant to Rule 144A and Regulati
December 21, 2016	EX-10.2	Purchase Agreement, dated December 15, 2016, by and between NantHealth, Inc. and Cambridge Equities, L.P. EX-10.2 Exhibit 10.2 PURCHASE AGREEMENT Cambridge Equities, L.P. (the ?Undersigned?), is entering into this Purchase Agreement (the ?Agreement?) with NantHealth, Inc. (the ?Company?) on December 15, 2016 whereby the Undersigned will purchase (the ?Purchase?) the Company?s 5.50% Convertible Senior Notes due 2021 (the ?Notes?) having the terms set forth on Exhibit A hereto that will be issued pursua
December 21, 2016	EX-4.1	Form of 5.50% Convertible Senior Note due 2021 (included in Exhibit 4.1). EX-4.1 Exhibit 4.1 Execution Version NANTHEALTH, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of December 21, 2016 5.50% Convertible Senior Notes due 2021 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 13 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation and
December 21, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 15, 2016 NantHealth, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation or organ
December 21, 2016	EX-10.3	Second Amended and Restated Promissory Note, dated December 15, 2016, by and between NantHealth, Inc. and Nant Capital LLC. EX-10.3 Exhibit 10.3 SECOND AMENDED AND RESTATED PROMISSORY NOTE December 15, 2016 Culver City, California WHEREAS, NantHealth, Inc. (formerly Nant Health, LLC), a Delaware corporation, with offices at 9920 Jefferson Boulevard, Culver City, California 90232 (the ?Company?), entered into a demand promissory note dated January 4, 2016 (the ?Original Note?) in favor of Nant Capital, LLC, with offices
December 15, 2016	EX-99.1	NantHealth, Inc. Announces Proposed $100 Million Convertible Notes Offering EX-99.1 Exhibit 99.1 NantHealth, Inc. Announces Proposed $100 Million Convertible Notes Offering Culver City, California ? December 15, 2016 ? NantHealth, Inc. (Nasdaq: NH) today announced its intention to offer, subject to market conditions and other factors, $100 million aggregate principal amount of convertible senior notes due 2021 (the ?notes?) in a private placement to qualified institutiona
December 15, 2016	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2016 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission
November 10, 2016	10-Q	NantHealth 10-Q (Quarterly Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-37
November 10, 2016	EX-10.1	Second Amended and Restated NantOmics Exclusive Reseller Agreement, dated as of September 20, 2016, by and between the Registrant and NantOmics, LLC. Exhibit 10.1 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. SECOND AMENDED AND RESTATED NANTOMICS EXCLUSIVE RESELLER AGREEMENT This Second Amended and Restated NantOmics Exclusive Reseller Agreement (this “Agreement”) is made as of September 20
November 7, 2016	EX-99.1	NANTHEALTH REPORTS 76% INCREASE IN TOTAL Q3 NET REVENUE 2016 VS 2015, GROSS PROFIT TRIPLES RAPID ADOPTION OF GPS CANCER WITH MORE THAN 100% INCREASE IN THE NUMBER OF ONCOLOGISTS ORDERING THE TEST FROM SECOND TO THIRD QUARTER Exhibit Exhibit 99.1 Investor Contact: Robert Jaffe [email protected] 424.288.4098 NANTHEALTH REPORTS 76% INCREASE IN TOTAL Q3 NET REVENUE 2016 VS 2015, GROSS PROFIT TRIPLES RAPID ADOPTION OF GPS CANCER WITH MORE THAN 100% INCREASE IN THE NUMBER OF ONCOLOGISTS ORDERING THE TEST FROM SECOND TO THIRD QUARTER ? Number of Oncologists Ordering GPS Cancer Increased from 85 in Q2 to 181 in Q3, Represen
November 7, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2016 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commissi
September 15, 2016	8-K	Regulation FD Disclosure 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 15, 2016 NantHealth, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37792 27-3019889 (State or other jurisdiction of incorporation) (Commission
September 14, 2016	10-Q/A	NH / NantHealth, Inc. 10-Q/A - Quarterly Report - 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 0
August 15, 2016	10-Q	NH / NantHealth, Inc. 10-Q - Quarterly Report - 10-Q 10-Q 1 a8152016filing10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission
August 15, 2016	EX-3.2	Amended and Restated Bylaws. Exhibit 3.2 FORM OF AMENDED AND RESTATED BYLAWS OF NANTHEALTH, INC. (as amended and restated on June 7, 2016, and effective immediately as of the closing of the corporation’s initial public offering) TABLE OF CONTENTS Page ARTICLE I — CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II — MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEET
August 15, 2016	EX-3.1	Amended and Restated Certificate of Incorporation. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NANTHEALTH, INC. NantHealth, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: A. The Corporation was first formed on July 7, 2010 as “About Advanced Health, LLC” in Delaware as a Limited Liability Company and was converted into NantHealth, Inc. on June 1, 2016. B.
August 15, 2016	10-Q	NH / NantHealth, Inc. 10-Q - Quarterly Report - 10-Q 10-Q 1 a8152016filing10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission

NH / NantHealth Inc - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)